Page last updated: 2024-10-17

creatine and Clostridioides difficile Infection

creatine has been researched along with Clostridioides difficile Infection in 2 studies

Research Excerpts

ExcerptRelevanceReference
"The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade."2.79Risk estimation for recurrent Clostridium difficile infection based on clinical factors. ( Collins, SH; D'Agostino, RB; Gorbach, S; Kean, Y; Pencina, KM, 2014)
"In conclusion, both leukocytosis and renal failure are useful predictors, although timing of measurement is important."1.38Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. ( Bauer, MP; Dale, AP; Fawley, WN; Gerding, DN; Gorbach, SL; Hensgens, MP; Kuijper, EJ; Miller, MA; Wilcox, MH, 2012)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
D'Agostino, RB1
Collins, SH1
Pencina, KM1
Kean, Y1
Gorbach, S1
Bauer, MP1
Hensgens, MP1
Miller, MA1
Gerding, DN1
Wilcox, MH1
Dale, AP1
Fawley, WN1
Kuijper, EJ1
Gorbach, SL1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)[NCT00468728]Phase 3535 participants (Actual)Interventional2006-10-04Completed
A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea[NCT00314951]Phase 3629 participants (Actual)Interventional2006-05-02Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cure Rate at End of Therapy

Percentage of subjects with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. (NCT00468728)
Timeframe: Study day 10 (+/- 2 days)

InterventionPercentage of Participants (Number)
Vancomycin86.7
PAR-101/OPT-8087.7

Global Cure

Achieving a cure response at end of treatment and not having a recurrence at any time up to the post-study visit. (NCT00468728)
Timeframe: End of Study

InterventionPercentage of Participants (Number)
Vancomycin63.3
PAR-101/OPT-8076.7

Recurrence

Percentage of subjects with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. (NCT00468728)
Timeframe: Study days 11-40

InterventionPercentage of Participants (Number)
Vancomycin27.0
PAR-101/OPT-8012.6

Cure Rate at End of Therapy

Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. (NCT00314951)
Timeframe: Study day 10 (+/- 2 days)

InterventionPercentage of Participants (Number)
Vancomycin85.7
Fidaxomicin88.2

Global Cure

Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40. (NCT00314951)
Timeframe: End of Study (Day 40)

InterventionPercentage of Participants (Number)
Vancomycin64.2
Fidaxomicin74.4

Recurrence

Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. (NCT00314951)
Timeframe: Study days 11-40

InterventionPercentage of Participants (Number)
Vancomycin25.1
Fidaxomicin15.7

Trials

1 trial available for creatine and Clostridioides difficile Infection

ArticleYear
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid

2014
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid

2014
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid

2014
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Volume: 58, Issue:10

    Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid

2014

Other Studies

1 other study available for creatine and Clostridioides difficile Infection

ArticleYear
Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55 Suppl 2

    Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Confidence

2012